Why a onetime biotech IPO hopeful shifted to a ‘blank check’ deal

Aiming at a deadly lung-scarring disease that has stopped other drug developers, a Peninsula biotech company plans to raise $254.3 million through a blank-check company merger and move a drug into mid-stage clinical trials next year. Blade Therapeutics Inc. would get $230 million via the special purpose acquisition...

Click to view original post